Welcome to our dedicated page for Armor US Equity ETF news (Ticker: ARMR), a resource for investors and traders seeking the latest updates and insights on Armor US Equity ETF stock.
ARMR develops biodefense-tech countermeasures against fentanyl and other emerging synthetic drug threats. Company news centers on its pre-exposure biodefense platform, including a lead immunotherapy intended to provide preventive annual protection against illicit fentanyl, as well as capital-formation activity involving convertible preferred stock offerings to support platform development.
ARMR Sciences Inc. has launched a capital raise of up to $30 million, expandable to $50 million, through a private placement of Series A-1, 7% Convertible Preferred Stock. The company is developing biodefense solutions against fentanyl and synthetic drug threats, with plans for a public offering and Nasdaq listing in late 2025 or early 2026.
The company's flagship product, ARMR-100, is an immunotherapy developed at the University of Houston that showed promising results in animal studies, preventing 92% of fentanyl from entering the brain and achieving 100% blockage of the drug's effects. The technology demonstrated no cross-reactivity with common pain medications. ARMR plans to begin human trials in partnership with the Center for Human Drug Research (CHDR).
Additionally, ARMR is establishing ARMR Defense Labs to develop an AI-powered drug discovery platform for creating countermeasures against emerging synthetic threats.
Summary not available.